SG11201803701YA - Methods and compositions for gene editing in hematopoietic stem cells - Google Patents

Methods and compositions for gene editing in hematopoietic stem cells

Info

Publication number
SG11201803701YA
SG11201803701YA SG11201803701YA SG11201803701YA SG11201803701YA SG 11201803701Y A SG11201803701Y A SG 11201803701YA SG 11201803701Y A SG11201803701Y A SG 11201803701YA SG 11201803701Y A SG11201803701Y A SG 11201803701YA SG 11201803701Y A SG11201803701Y A SG 11201803701YA
Authority
SG
Singapore
Prior art keywords
international
pennsylvania
hematopoietic stem
philadelphia
methods
Prior art date
Application number
SG11201803701YA
Inventor
Saar Gill
Miriam Kim
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG11201803701YA publication Critical patent/SG11201803701YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ires.. 00) (43) International Publication Date ..... ..r ,„,„01 11 May 2017(11.05.2017) WIPO I PCT (10) WO International Publication Number 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/079400 Al (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 35/15 (2015.01) A61K 48/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 35/17 (2015.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 45/06 (2006.01) A61P 35/02 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2016/060273 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 3 November 2016 (03.11.2016) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/250,561 4 November 2015 (04.11.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant . THE TRUSTEES OF THE UNIVERSITY DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Suite 200, Philadelphia, Pennsylvania 19104 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: GILL, Saar; 30 North Third Street, Apt. 4A, GW, KM, ML, MR, NE, SN, TD, TG). Philadelphia, Pennsylvania 19106 (US). KIM, Miriam; Declarations under Rule 4.17: 2400 Chestnut Street, Apt. 2604, Philadelphia, of inventorship (Rule 4.17(iv)) Pennsylvania 19103 (US). Published: (74) Agents: DOYLE, Kathryn et al.; Saul Ewing LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, — with international search report (Art 21(3)) Pennsylvania 19102 (US). — with sequence listing part of description (Rule 5.2(a)) Designated (81) States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (54) Title: METHODS AND COMPOSITIONS FOR GENE EDITING IN HEMATOPOIETIC STEM CELLS A. trunc-gRNAvI trunc-gRNAv2 hum- RNAv3 trunc-gR NAv5 1-1 . .4t i I i CD33n ;40.3 S r x :310 1 0 / 0 it Cr\ IN O ir.... (57) : The present invention relates to compositions and 1-1 c:::, cells. One aspect of the invention includes a modified hematopoietic stem or progenitor cell comprising a nucleic acid capable of de N creasing expression of an endogenous gene or a portion thereof, wherein 0 antigen domain targeted by a chimeric antigen receptor (CAR). Another ,1 . modified hematopoietic stem or progenitor cell. Also included are fled cell for adoptive therapy and treating a condition, such as an autoimmune 1)33neg 364 ^890 , 1 t Figures 1 methods of generating modified hematopoietic stem or progenitor - the endogenous gene encodes a polypeptide comprising an aspect of the invention includes a method for generating a methods and pharmaceutical compositions comprising the modi - disease or cancer.
SG11201803701YA 2015-11-04 2016-11-03 Methods and compositions for gene editing in hematopoietic stem cells SG11201803701YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250561P 2015-11-04 2015-11-04
PCT/US2016/060273 WO2017079400A1 (en) 2015-11-04 2016-11-03 Methods and compositions for gene editing in hematopoietic stem cells

Publications (1)

Publication Number Publication Date
SG11201803701YA true SG11201803701YA (en) 2018-06-28

Family

ID=58662736

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201803701YA SG11201803701YA (en) 2015-11-04 2016-11-03 Methods and compositions for gene editing in hematopoietic stem cells
SG10202107602XA SG10202107602XA (en) 2015-11-04 2016-11-03 Methods and compositions for gene editing in hematopoietic stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202107602XA SG10202107602XA (en) 2015-11-04 2016-11-03 Methods and compositions for gene editing in hematopoietic stem cells

Country Status (17)

Country Link
US (3) US10548922B2 (en)
EP (1) EP3370741A4 (en)
JP (3) JP6866385B2 (en)
KR (1) KR20180073679A (en)
CN (1) CN108463227A (en)
AU (2) AU2016349280B2 (en)
BR (1) BR112018009098A8 (en)
CA (1) CA3004053A1 (en)
CL (1) CL2018001198A1 (en)
EA (1) EA201891092A1 (en)
HK (1) HK1259151A1 (en)
IL (1) IL259084A (en)
MX (1) MX2018005612A (en)
MY (1) MY185961A (en)
PH (1) PH12018500965A1 (en)
SG (2) SG11201803701YA (en)
WO (1) WO2017079400A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (en) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
ES2692206T3 (en) 2014-11-26 2018-11-30 Miltenyi Biotec Gmbh Combined immunotherapy of antigen and hematopoietic recognition receptors for the treatment of diseases
CA3001859A1 (en) 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
SG11201803701YA (en) * 2015-11-04 2018-06-28 Univ Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
KR102547316B1 (en) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Adenosine nucleobase editing agents and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (en) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Aav delivery of nucleobase editors
IL266362B1 (en) * 2016-11-02 2024-03-01 Univ Basel Immunologically discernible cell surface variants for use in cell therapy
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
MX2019010196A (en) * 2017-02-28 2019-12-19 Vor Biopharma Inc Compositions and methods for inhibition of lineage specific proteins.
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
JP2021523745A (en) 2018-05-16 2021-09-09 シンテゴ コーポレイション Methods and systems for guide RNA design and use
IL260445B (en) * 2018-07-05 2019-08-29 Lempo Therapeutics Ltd Methods and compositions for modulating myeloperoxidase (mpo) expression
KR20220036908A (en) 2018-08-28 2022-03-23 보르 바이오파마 인크. Genetically engineered hematopoietic stem cells and uses thereof
KR20210061397A (en) * 2018-09-19 2021-05-27 후지필름 셀룰러 다이내믹스, 인코포레이티드 Protein L for activation and expansion of chimeric antigen receptor-modified immune cells
KR20210105344A (en) * 2018-10-31 2021-08-26 휴머니건, 아이엔씨. Substances and methods for the treatment of cancer
CN109852627B (en) * 2018-12-26 2022-07-05 中国人民解放军军事科学院军事医学研究院 Plasmid for CRISPR system, construction method thereof and application of plasmid in targeted silencing of target gene of plague bacteria
AU2020207962A1 (en) * 2019-01-18 2021-07-22 University Of Southern California Methods and compositions to improve the safety and efficacy of cellular therapies
US20220202900A1 (en) * 2019-02-22 2022-06-30 The Trustees Of The University Of Pennsylvania Compositions and methods for crispr/cas9 knock-out of cd33 in human hematopoietic stem / progenitor cells for allogenic transplantation in patients with relapsed - refractory acute myeloid leukemia
CA3130789A1 (en) 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
CA3130488A1 (en) 2019-03-19 2020-09-24 David R. Liu Methods and compositions for editing nucleotide sequences
CN114787352A (en) * 2019-08-28 2022-07-22 Vor生物制药股份有限公司 Compositions and methods for CD123 modification
EP4022063A1 (en) * 2019-08-28 2022-07-06 Vor Biopharma Inc. Compositions and methods for cll1 modification
KR20210109971A (en) 2020-02-28 2021-09-07 현대자동차주식회사 Manufacturing method of negative electrode for lithium ion battery and lithium ion battery including negative electrode manufactured by the method
GB2614813A (en) 2020-05-08 2023-07-19 Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022228471A1 (en) * 2021-04-27 2022-11-03 上海驯鹿生物技术有限公司 Gene-edited hematopoietic stem cell and combined use thereof with car-t cell
WO2022232411A2 (en) * 2021-04-28 2022-11-03 Eisai R&D Mangement Co., Ltd. Antisense oligonucleotides and their use for treatment of neurodegenerative disorders
WO2023086422A1 (en) * 2021-11-09 2023-05-19 Vor Biopharma Inc. Compositions and methods for erm2 modification
WO2023137335A2 (en) * 2022-01-11 2023-07-20 Actinium Pharmaceuticals, Inc. Methods for treating cd33-positive hematological malignancies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100172882A1 (en) * 2007-01-11 2010-07-08 Glazer Peter M Compositions and methods for targeted inactivation of hiv cell surface receptors
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US9573988B2 (en) * 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
AU2014273490B2 (en) * 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
IL280215B (en) * 2014-04-07 2022-07-01 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CA3001859A1 (en) * 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
SG11201803701YA (en) * 2015-11-04 2018-06-28 Univ Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells

Also Published As

Publication number Publication date
US10548922B2 (en) 2020-02-04
JP2023115069A (en) 2023-08-18
MX2018005612A (en) 2018-11-09
CA3004053A1 (en) 2017-05-11
EP3370741A1 (en) 2018-09-12
CN108463227A (en) 2018-08-28
JP7378439B2 (en) 2023-11-13
BR112018009098A8 (en) 2019-02-26
IL259084A (en) 2018-06-28
EP3370741A4 (en) 2019-04-24
HK1259151A1 (en) 2019-11-29
AU2024200000A1 (en) 2024-03-21
EA201891092A1 (en) 2018-10-31
US20240066064A1 (en) 2024-02-29
US11771719B2 (en) 2023-10-03
AU2016349280A1 (en) 2018-05-24
MY185961A (en) 2021-06-14
AU2016349280B2 (en) 2023-10-05
PH12018500965A1 (en) 2018-11-12
US20180250339A1 (en) 2018-09-06
WO2017079400A1 (en) 2017-05-11
JP2018533625A (en) 2018-11-15
JP2021106595A (en) 2021-07-29
CL2018001198A1 (en) 2018-09-21
BR112018009098A2 (en) 2018-11-06
US20200281975A1 (en) 2020-09-10
SG10202107602XA (en) 2021-08-30
KR20180073679A (en) 2018-07-02
JP6866385B2 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201909949XA (en) Targeted immunotolerance
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201908391XA (en) Methods for modulating an immune response
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201809040YA (en) Hybrid aerosol-generating element and method for manufacturing a hybrid aerosol-generating element
SG11201805792PA (en) Chimeric proteins and methods of regulating gene expression
SG11201908624SA (en) Aryl hydrocarbon receptor antagonists and uses thereof
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201806988UA (en) Improved differentiation method
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201805645QA (en) Lsd1 inhibitors
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE